XTRA:MRKPharmaceuticals
A Look At Merck KGaA (XTRA:MRK) Valuation After Advancing Enpatoran To Global Phase 3 Lupus Trials
Merck KGaA (XTRA:MRK) has drawn fresh attention after dosing the first patient in its global Phase 3 ELOWEN-1 and ELOWEN-2 trials of enpatoran in lupus with active skin manifestations, marking a late stage pipeline milestone.
See our latest analysis for Merck KGaA.
The ELOWEN Phase 3 update and the recent Hybrid Drugs collaboration with Remepy come as Merck KGaA’s 7 day share price return of 5.08% and 1 day gain of 2.85% contrast with a 1 year total shareholder return decline of 4.23% and a 3...